Live Breaking News & Updates on Indiana University Publish Results

Search jobs
11-Feb-2021
Heidelberg Pharma and Indiana University Publish Results on HER2-ATAC for Targeted Immunotherapy of Triple Negative Breast Cancer in Science Translational Medicine
DGAP-News: Heidelberg Pharma AG
/ Key word(s): Miscellaneous
11.02.2021 / 07:58
PRESS RELEASE
Heidelberg Pharma and Indiana University Publish Results on HER2-ATAC for Targeted Immunotherapy of Triple Negative Breast Cancer in
Science Translational Medicine
- Extraordinary efficacy of a HER2-targeting Trastuzumab-ATAC in the treatment of Triple-Negative Breast Cancer (TNBC) with low HER2 expression and hemizygous deletion of chromosome 17p in preclinical models
- Induction of immunogenic cell death by an HER2-ATAC - Synergistic and increased efficacy in combination with checkpoint inhibitors ....

United States , Sylvia Wimmer , Andreas Pahl , Heidelberg Pharma , Indiana University , Mc Services , School Of Medicine , Frankfurt Stock Exchange , Distribution Services , Indiana University Publish , Corporate Communications , Indiana University Publish Results , Triple Negative Breast Cancer , Science Translational , Antibody Targeted Amanitin Conjugate , Science Translational Medicine , Triple Negative Breast Cancers , Chief Scientific Officer , Drug Conjugates , Targeted Amanitin Conjugates , Corporate News , Regulatory Announcements , ஒன்றுபட்டது மாநிலங்களில் , சில்வியா வீம்மேர் , ஆண்ட்ரியாஸ் பால் , ஹைடெல்பெர்க் பார்மா ,